Methods of Determining Cellular Chemosensitivity
First Claim
Patent Images
1. A method of predicting sensitivity of a cancer cell to a therapeutic agent comprising contacting said cell or cellular component thereof with a BH3 domain peptide and detecting apoptosis of said cell, wherein the presence of apoptosis indicate said cell is sensitive to a therapeutic agent.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods of determining cell sensitivity to a therapeutic agent.
-
Citations
15 Claims
- 1. A method of predicting sensitivity of a cancer cell to a therapeutic agent comprising contacting said cell or cellular component thereof with a BH3 domain peptide and detecting apoptosis of said cell, wherein the presence of apoptosis indicate said cell is sensitive to a therapeutic agent.
-
2. A method of predicting sensitivity of a cancer cell to a therapeutic agent comprising contacting mitochondria from said cell with a BH3 domain peptide or mimetic thereof and detecting cytochrome C release from said mitochondria, wherein the cytochrome C release indicates said cell is sensitive to a therapeutic agent.
-
3. A method of selecting an agent that is therapeutic for a subject comprising:
-
a) providing a cancer cell or cellular component thereof from said subject; b) contacting said cancer cell with a BH3 domain peptide or mimetic thereof, b) determining whether or not said BH3 domain peptide or mimetic induces apoptosis in said cancer cell to produce a test BH3 profile; c) comparing said test BH3 profile with a therapeutic agent BH3 profile; wherein a similarity of said test BH3 profile compared to said therapeutic agent BH3 profile indicates that the agent is therapeutic for said subject.
-
-
4. A method of predicting sensitivity of a cancer cell to a therapeutic agent comprising providing a BH3 profile of said cancer cell and comparing said BH3 profile to a control profile, wherein a similarity of said BH3 profile in said cancer cell compared to said control profile indicate said cancer cell is sensitive to said therapeutic agent.
-
12. A profile, comprising a pattern of mitochondrial sensitivity to BH3 peptides selected from the group consisting of SEQ ID NO:
- 1-12 and 13 taken from one or more subjects who have cancer.
- 13. A cell based assay system comprising permeabilized labeled cell and a BH3 peptide or mimetic thereof.
Specification